Paint Therapeutics is reimagining drug delivery through the lungs. Our proprietary Peptide Drug Conjugate Platforms  enable targeted pulmonary delivery with precise control over drug release and systemic exposure. We improve efficacy, reduce toxicity, and unlock new IP for therapies limited by oral administration, first-pass metabolism, or short half-lives. With PulmoPaint™ and SystemoPaint™, we have developed targeted delivery technologies that address longstanding limitations in efficacy, safety, and bioavailability.

Paint Therapeutics

Org chart

Teams

Offices